The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 0.13 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.87 — no flag raisedOK
- Earnings quality 79/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Vanda Pharmaceuticals Inc. reports it. History and quarterly detail are in the app.
- Fanapt®$117.3M
- Hetlioz$71.4M
- PONVORY®$27.4M
Leadership changes
From Vanda Pharmaceuticals Inc.'s own filings, the day they're filed.
- Timothy Williams · President · departureeff. 2026-04-10
- Charles C. Duncan · director · appointment
Latest filings
- 8-K · Company announcement2026-06-05
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-06
- DEF 14A · Annual proxy (pay & governance)2026-04-23
- 8-K · Company announcement2026-04-22
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Vanda Pharmaceuticals Inc., every answer cited🔒
- The Intelligence Brief — added when Vanda Pharmaceuticals Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.